sFlt Multivalent Conjugates Inhibit Angiogenesis and Improve Half-Life In Vivo

Area of Science:

• Ophthalmology
• Biotechnology
• Drug Delivery

Background:

• Current anti-VEGF treatments for diabetic retinopathy require frequent injections due to short ocular residence time.
• This leads to poor patient compliance and disease progression.

Purpose of the Study:

• To develop an anti-VEGF drug with improved intravitreal residence time.
• To enhance the efficacy and patient compliance for diabetic retinopathy treatment.

Main Methods:

• Synthesized multivalent bioconjugates (mvsFlt) by grafting anti-VEGF protein (sFlt) to hyaluronic acid (HyA).
• Assessed bioactivity using a mouse corneal angiogenesis assay.
• Evaluated intravitreal residence time and half-life in a rat vitreous model.
• Tested efficacy in an oxygen-induced retinopathy model.

Main Results:

• Conjugation to HyA did not affect sFlt bioactivity.
• mvsFlt demonstrated significantly increased intravitreal residence time (35 hours vs. 3.3 hours for sFlt).
• mvsFlt showed greater efficacy in inhibiting retinal neovascularization compared to unconjugated sFlt.

Conclusions:

• Conjugation of sFlt to HyA enhances drug half-life without compromising VEGF binding affinity.
• This multivalent conjugation strategy offers a promising approach to improve anti-VEGF therapy for diabetic retinopathy.
• The improved drug half-life has the potential to increase treatment efficacy and patient quality of life.